الفهرس 
CK-MB IsoformsOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
100 patients were randomized whether to receive or not to receive 60 mg oral loading dose of Trimetazidine before elective percutaneous coronary intervention by 30 minutes, CK-MB and Troponin. I were measured at 0 and 18 hours post PCI.
Results: The post-procedural elevation in Trop.I in the group of patients preloaded with Trimetazidine was significantly lower than the other group (p <0.05), also the mean peak CK-MB was significantly lower in the group of patients preloaded with Trimetazidine (p <0.05).
Conclusion: There is a trend towards reduction of postprocedural elevations of cardiac biomarkers in patients treated with Trimetazidine, Owing to the fact that the postprocedural elevation of cardiac biomarkers carries adverse prognostic effects, and because Trimetazidine is devoid of hemodynamic effects and has overall excellent clinical tolerance, it is an attractive candidate as adjunctive treatment to PCI to decrease periprocedural myocardial injury